Table 1 Demographic and baseline characteristics of patients
From: Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients
Lymphoma | Myeloma | |||||
|---|---|---|---|---|---|---|
Biosim G-CSF | Class G-CSF | P | Biosim G-CSF | Class G-CSF | P | |
Nb | 25 | 25 | NS | 13 | 25 | NS |
Sex M/F | 16/9 | 16/9 | NS | 8/5 | 16/9 | NS |
Age | 55 | 54 | NS | 57 | 58 | NS |
CR 21 | CR 19 | CR 5 | CR 6 | |||
Status before | PR 3 | PR 6 | NS | VGPR 3 | VGPR 6 | NS |
PBSCT | PROG 1 | PROG 0 | PR 5 | PR 12 | ||
SD 1 | ||||||
